Audited financial results for FY ended March 31, 2025 and dividend
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Fermenta Biotech approved audited financial results (standalone and consolidated) for Q4 and FY ended March 31, 2025, along with a clean (unmodified) opinion from auditors SRBC & Co. LLP. On a standalone basis, revenue from operations grew to Rs. 43,053.17 lakhs from Rs. 31,524.46 lakhs in FY24 (up ~37%), while the company swung from a loss after tax of Rs. 1,874.33 lakhs to a profit of Rs. 6,687.07 lakhs. Consolidated revenue rose to Rs. 46,947.73 lakhs from Rs. 34,747.02 lakhs (~35% growth), with PAT turning around from a loss of Rs. 2,416.29 lakhs to a profit of Rs. 7,495.60 lakhs. The Board recommended a final dividend of Rs. 2.50 per share (50% on face value of Rs. 5), subject to shareholder approval at the AGM on August 12, 2025, with record date of August 6, 2025.
Strong turnaround story with revenue growth above 35% and a sharp swing to profitability, supported by a clean audit and a 50% dividend declaration. Positive signal for shareholders, likely to be viewed favourably by the market.